Moderna (MRNA) Market Capitalization (2018 - 2026)

Moderna (MRNA) has reported Market Capitalization for 9 consecutive years, with $27.9 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Market Capitalization rose 160.35% year-over-year to $27.9 billion in Q2 2026; TTM through Jun 2026 was $27.9 billion, a 160.35% increase from a year earlier, with the FY2025 full-year figure at $11.6 billion, down 27.61% from the prior year.
• Market Capitalization was $27.9 billion for Q2 2026 at Moderna, up from $20.2 billion in the prior quarter.
• Over five years, Market Capitalization peaked at $69.2 billion in Q4 2022 and troughed at $10.1 billion in Q3 2025.
• A 5-year average of $35.7 billion and a median of $38.7 billion in 2023 frame the typical range for Market Capitalization.
• Across the five-year window, Market Capitalization plunged 76.46% in 2025 and jumped 160.35% in 2026, its largest moves.
• Over 5 years, Market Capitalization stood at $69.2 billion in 2022, then tumbled by 45.06% to $38.0 billion in 2023, then plunged by 57.75% to $16.0 billion in 2024, then fell by 27.61% to $11.6 billion in 2025, then surged by 140.48% to $27.9 billion in 2026.
• The last three Market Capitalization figures came in at $27.9 billion (Q2 2026), $20.2 billion (Q1 2026), and $11.6 billion (Q4 2025), per Business Quant data.